Pathkey.AI Limited (ASX:PKY), an AI-powered platform technology company, has announced the appointment of Mr Andrew Farnsworth as Chief Executive Officer with effect from 11 May 2026. Mr Farnsworth has been engaged as a consultant to the company over the preceding six months as part of a strategic review aimed at refining PKY's positioning as an applied AI Business with capabilities extending beyond healthcare, while retaining its TrialKey Clinical Trials design platform as the lead commercial product. He has also been instrumental in supporting the Board's decision to pursue the recently-announced binding Acquisition of Singapore-based Chipforge, a company developing an AI-powered chip design platform for semiconductor engineering.

The disclosure includes a detailed Annexure A summarising the material terms of Mr Farnsworth's executive services contract. The base salary is A$270,000 per annum plus Superannuation, with a short-term incentive of up to A$135,000 contingent on FY27 group Revenue hurdles, and a long-term incentive comprising 46,000,000 performance rights across four equally-weighted tranches with time-based, market-price, product-delivery and Partnership-execution vesting conditions. The LTI is subject to Shareholder approval at a forthcoming meeting. The announcement is significant for PKY because the chief executive role anchors the company's pivot from a primarily clinical-trial-focused platform toward a multi-platform applied AI strategy that includes semiconductor design tooling and other regulated-industry use cases.

What was announced

Pathkey has announced the appointment of Mr Andrew Farnsworth as Chief Executive Officer of the group, effective immediately. The announcement positions Mr Farnsworth as a defence-grounded technology, product and commercialisation leader with more than 20 years of experience. His career began in the Royal Australian Air Force, where he worked in communications and IT operations including high-security radio and encrypted communications in mission-critical environments. Subsequent roles spanned defence-aligned and government environments, including secure systems work involving cryptographic equipment, encrypted endpoints and protected networks.

More recently, Mr Farnsworth has held senior executive technology roles in large global enterprises. At Yum! Brands (NYSE: YUM, identified by PKY as having a US$43 billion Market Capitalisation), he directed technology strategy and product development across E-commerce, payments, AI/Machine Learning, restaurant systems and data platforms, with PKY stating he helped grow digital revenue to approximately US$1.5 billion. Earlier executive roles include Sephora Asia, where he led regional enterprise technology, and Marina Bay Sands, where he oversaw Cybersecurity, infrastructure, enterprise architecture, surveillance systems and data centre modernisation. The company also notes founder-led product development experience, including a secure mobile payments and customer engagement platform.

Chair Shannon Robinson commented that the appointment comes at a pivotal point in the company's development given the planned Chipforge acquisition. Mr Farnsworth highlighted his focus on "near-term commercialisation" and on unlocking synergies between TrialKey and Chipforge. Annexure A to the release sets out the executive services agreement.

Key facts and figures

The remuneration structure has several discrete components. The base salary is A$270,000 per annum plus statutory superannuation. The short-term incentive of up to A$135,000 cumulative is payable in cash subject to audited FY27 revenue (excluding rebates): A$67,500 if FY27 revenue is at least $200,000 but less than $500,000, or A$135,000 if FY27 revenue is at least $500,000.

The long-term incentive comprises 46,000,000 performance rights, split into four tranches of 11,500,000 rights each, all subject to shareholder approval. Tranche 1: rights expiring three years from issue, vesting on the last day of each of four consecutive three-month periods, conditional on continued service. Tranche 2: rights expiring three years from issue, vesting if the 15-day VWAP of PKY shares on ASX reaches or exceeds A$0.06 per share. Tranche 3: rights expiring 18 months from issue, vesting on delivery of a minimum viable product within nine months from issue and subject to verification by an independent expert from a recognised Australian or Singaporean university. The MVP must be a functional version utilising Chipforge intellectual property, deliver core features for end-users in a real-world working environment, and enable potential clients to verify the functionality of efficient semiconductor development. Tranche 4: rights expiring three years from issue, vesting on execution of a binding strategic partnership or customer agreement that embeds TrialKey within the partner's operational workflow for ongoing commercial use. The appointment is on a no-fixed-term basis with a three-month notice period (one month if the Chipforge acquisition does not proceed).

Why the announcement matters

A CEO appointment is one of the most material governance decisions a listed company can make, particularly for a small-capitalisation business mid-pivot. Pathkey's communicated strategy is to expand from a single-platform healthcare-focused company (TrialKey) to a multi-platform applied AI business that includes Chipforge in the semiconductor design domain and aspires to serve customers in defence, critical infrastructure and other regulated industries. The CEO selection therefore signals the type of Leadership the Board considers necessary for that pivot.

The choice of an executive with both defence/security and large-enterprise commercialisation experience is informative. Defence-style secure systems experience aligns with the company's stated intent to serve regulated industries where reliability, security and traceability are non-Negotiable. Large-enterprise experience at Yum! Brands, Sephora Asia and Marina Bay Sands is presented by PKY as evidence that the CEO can scale platforms and drive revenue.

For investors, the announcement also matters because the remuneration structure provides a relatively unusual level of granularity on what the Board considers the value-driving milestones. Revenue hurdles for the STI, a 15-day VWAP of A$0.06 for one LTI tranche, a nine-month MVP target supported by independent academic verification, and a TrialKey embedment-style partnership are all explicit, time-bound benchmarks. They provide investors with an articulated, transparent yardstick against which to track the management team's progress.

Strategic context

Pathkey describes itself as an Australian platform technology company developing proprietary AI-powered large language model solutions for data-intensive industries. Its core technology, TrialKey, focuses on clinical trial design and optimisation. PKY has entered into a binding agreement to acquire Chipforge, a Singapore-based company developing an AI-powered chip design platform for semiconductor engineering. The company states that both platforms are built on an agent-based AI architecture combining large language model functionality with neuro-symbolic reasoning, with AI agents iteratively generating, evaluating and refining candidate solutions through a reinforcement-driven optimisation loop.

The strategic rationale articulated in the announcement is that Mr Farnsworth's experience straddles secure systems, enterprise transformation, product execution and founder-led commercialisation — a combination relevant to a company attempting to commercialise enterprise-grade AI tooling in regulated markets. The Chipforge acquisition, if completed, would extend the company's addressable market into semiconductor engineering, an area characterised by long design cycles, high Capital intensity and significant existing electronic-design-automation incumbents.

The LTI structure ties Mr Farnsworth's most economically significant compensation to the same milestones that would, if achieved, validate the strategy: revenue traction (STI), share-price re-rating to A$0.06 (Tranche 2 LTI), MVP delivery on Chipforge IP (Tranche 3 LTI), and a TrialKey partnership embedding (Tranche 4 LTI). This is a relatively well-aligned structure for a pre-revenue or early-revenue technology company.

Investor takeaway

The appointment of Mr Andrew Farnsworth as CEO is a meaningful step for Pathkey. It places at the helm an experienced enterprise-AI executive at a time when the company is attempting to broaden its platform strategy and to integrate a Singapore-based semiconductor-design acquisition. The remuneration structure is transparent and milestone-linked, providing investors with explicit benchmarks for monitoring progress.

However, the value of the appointment will be determined by execution. Investors should observe the timing and terms of completion of the Chipforge acquisition, the trajectory of FY27 revenue against the STI hurdles, progress toward MVP delivery on Chipforge IP within nine months from LTI issue, and any announced strategic partnership or customer agreement embedding TrialKey. The 15-day VWAP target of A$0.06 for Tranche 2 of the LTI provides a directly observable market signal of one share-price-based vesting condition. None of these milestones is guaranteed.